Summary
Corteva, Inc. reported net sales of $17.2 billion for the fiscal year 2023, a slight decrease of 1% compared to the previous year, primarily attributed to a 10% volume decline partially offset by a 7% price increase and a favorable portfolio impact from acquisitions. The company's operating EBITDA improved to $3.4 billion, driven by strong price execution and productivity initiatives. Corteva successfully integrated two biologicals companies, Stoller and Symborg, in early 2023, enhancing its crop protection portfolio. The company returned approximately $1.2 billion to shareholders through share repurchases and dividends in 2023, reflecting a commitment to capital deployment. Looking ahead to 2024, Corteva anticipates net sales between $17.4 billion and $17.7 billion and operating EBITDA between $3.5 billion and $3.7 billion, indicating confidence in continued growth and operational efficiency. Significant emphasis was placed on innovation and sustainability, with increased investment in R&D to deliver differentiated solutions. The company continues to manage risks associated with regulatory approvals, supply chain dynamics, and evolving market conditions, while also navigating ongoing litigation related to legacy EIDP businesses, particularly concerning PFAS matters.
Financial Highlights
54 data points| Revenue | $17.23B |
| Cost of Revenue | $9.92B |
| Gross Profit | $7.31B |
| R&D Expenses | $1.34B |
| SG&A Expenses | $3.18B |
| Net Income | $735.00M |
| EPS (Basic) | $1.04 |
| EPS (Diluted) | $1.03 |
| Shares Outstanding (Basic) | 709.00M |
| Shares Outstanding (Diluted) | 711.90M |
Key Highlights
- 1Net sales for fiscal year 2023 were $17.2 billion, a 1% decrease year-over-year, mainly due to lower volumes (down 10%) offset by price increases (up 7%) and portfolio impacts.
- 2Operating EBITDA improved to $3.4 billion, driven by price execution and productivity actions, despite lower volumes and cost/currency headwinds.
- 3Corteva completed the acquisitions of Stoller Group and Symborg, bolstering its Biologicals and microbiological technologies offerings in the Crop Protection segment.
- 4The company returned approximately $1.2 billion to shareholders in 2023 through share repurchases ($500 million) and dividends ($620 million).
- 5Corteva expects 2024 net sales to be in the range of $17.4 billion to $17.7 billion and Operating EBITDA between $3.5 billion and $3.7 billion.
- 6R&D expenses increased to $1.3 billion (8% of net sales) to support innovation and product pipeline development.
- 7The Seed segment saw a 5% increase in net sales to $9.5 billion, driven by a 13% price increase, while Segment Operating EBITDA grew 28% to $2.1 billion.
- 8The Crop Protection segment's net sales decreased by 9% to $7.8 billion due to lower volumes and currency impacts, with Segment Operating EBITDA down 18% to $1.4 billion.